甲状腺乳头状癌组织VEGF-C／D及受体和D2-40表达与淋巴结转移相关性分析  

Correlation analysis the expression of VEGF-C/D,its receptor and D2-40 with lymph node metastasis in papillary thyroid carcinoma

作　　者：黄静[1] 吴靖芳[2] 张静[2] 张文静[2] 刘军超[3] 薛刚[3] 

机构地区：[1]河北北方学院临床,河北张家口075000 [2]河北北方学院组织胚胎学教研室,河北张家口075000 [3]河北北方学院附属第一医院耳鼻咽喉头颈外科,河北张家口075000

出　　处：《中华肿瘤防治杂志》2013年第24期1904-1907,1911,共5页Chinese Journal of Cancer Prevention and Treatment

基　　金：河北省教育厅重点项目(ZD2010101);河北省科技厅项目(12276104D-91)

摘　　要：目的:分析VEGF-C/D及受体VEGFR-3和D2-40在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)组织中的表达及与淋巴结转移的关系。方法:应用免疫组化SP法检测2009-01-01-2012-10-28河北北方学院附属第一医院收治的68例PTC和30例甲状腺腺瘤患者组织中VEGF-C/D、VEGFR-3、D2-40的表达水平,比较VEGF-C/D和受体VEGFR-3在PTC和腺瘤,PTC有无淋巴结转移病例中的差异;并分别计数VEGFR-3和D2-40淋巴管密度(lymphatic vessel density,LVD)。结果:PTC和腺瘤组织中VEGF-C阳性率分别为85.29%和16.67%,χ2=47.70,P<0.001;VEGF-D阳性率分别为77.94%和13.33%,χ2=35.71,P<0.001;VEGFR-3阳性率分别为83.82%和13.33%,χ2=43.56,P<0.001;D2-40阳性率分别为79.41%和10.00%,χ2=35.19,P<0.001。PTC伴淋巴结转移组和无淋巴结转移组VEGF-C阳性率分别为100%和77.55%,χ2=3.876,P=0.034,r=0.259,P=0.024;VEGFR-3阳性率分别为100%和77.55%,χ2=5.088,P=0.027,r=0.274,P=0.024。PTC组和腺瘤组D2-40阳性LVD密度分别为3.4±0.4和0.5±0.4,t=12.526,P<0.001;VEGFR-3阳性LVD密度分别为4.1±0.7和0.7±0.6,t=3.163,P<0.001。PTC伴淋巴结转移组和无淋巴结转移组D2-40阳性LVD密度分别为5.6±3.7和2.7±1.5,t′=2.758,P=0.009;VEGFR-3阳性LVD密度分别为6.9±3.5和3.3±0.9,t′=3.224,P=0.002;癌周VEGFR-3阳性LVD密度(12.6±4.1)高于D2-40的(7.9±4.3),t=2.106,P=0.04。结论:甲状腺乳头状癌VEGF-C/D、VEGFR-3和D2-40高表达与淋巴结转移密切相关,联合检测可作为预测PTC淋巴结转移的重要指标。OBJECTIVE：To investigate the expression of VEGF-C/D,VEGFR-3 and D2 40 in papillary thyroid carci- noma （PTC） and the relationship with lymph node metastasis. METHODS： The expression of VEGF-C/D, VEGFR-3 and D2 40 in 68 cases of papillary thyroid carcinoma （PTC） and 30 cases of thyroid adenoma （TA） were detected by immuno- histochemical staining. The difference of VEGF C/D and VEGFR-3 in PTC and TA,PTC with lymph node metastasis and without metastasis was compared. The lymphatic vessel density（LVD） of VEGFR-3 and D2-40 was counted respectively. RESULTS：The positive rate of VEGF-C, VEGF-D, VEGFR-3 and D2-40 in PTC group was higher than those in TA group （85.29% vs 16.67%,x2 =47.70,P〈20. 001） ,（77.94% vs 13.33%,-K2 =35.71,P〈0.001）,（83.82% vs 13.33%,x2 = 43.56,P〈0.001）, （79.41% zJs 10.00%,-Kz --35. 19,P〈0. 001）. The positive rate of VEGF-C and VEGFR-3 in PTC with lymph node metastasis was higher than that without lymph node metastasis,and there was a positive relationship be tweenthe twoindexs and lymph node metastasis （100.00% vs 77.55%,X2=3.876,P=0.034,r=0.259,P-0.024,100.00 vs 77.55%; 2：5.014,P=0.025,r=0.274,P：0.024）.in group PTC,D2-40 and VEGFR-3 positive LVD were significantly higher than those of TA group（3.4±0.4 vs 0. 5±0. 4,t=2. 526,P〈0. 001;4.1±0.7 vs 0.7±0. 6, t 13. 163,P〈0. 001） ,and PTC with lymph node metastasis group was significantly higher than those without metastasis （5.6±3.7 vs 2.7±1.5,t=2. 758,P：0. 009;6.9!3.5 vs 3.3±0. 9,t=3. 224,P：0. 002）;Peri-carcinoma VEGFR-3 positive LVD （12.64±4.1） was higher than that of D2-40 （7.9±4.3） ,t=2. 106,P=0.04. CONCLUSIONS： The high ex pression of VEGF-C/D,VEGFR-3 and D2-40 in PTC are closely associated with lymph node metastasis. VEGF-C, VEG- FR3 ,D2 40 combined detection may be used as an important index in predicting lymph node metastasis.

关 键 词：癌 乳头状 病理学 甲状腺肿瘤病理学 淋巴结转移 VEGF—C D VEGFR-3 D2—40 免疫组织化学 

分 类 号：R736.1[医药卫生—肿瘤]